Acute ST-elevation myocardial infraction after use of oral sumatriptan: a rare presentation

Indira Sahu; Manish Ruhela; Rakesh Kumar Ola

doi:10.18203/2319-2003.ijbcp20204506

Authors

Indira Sahu Medical Officer, CHC, Laxmangarh, Sikar, Rajasthan, India
Manish Ruhela Department of Cardiology, Noble Care Hospital, Sikar, Rajasthan, India
Rakesh Kumar Ola Department of Cardiology, Noble Care Hospital, Sikar, Rajasthan, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20204506

Keywords:

Sumatriptan, Migraine, Myocardial infraction

Abstract

Sumatriptan is an agonist of 5-hydroxytryptamine type-1 (5HT1) receptors that is widely used as a migraine abortant; however, there have been studies showing angina, coronary vasospasm, and even myocardial infraction in patients with predisposing cardiac risk factors. We present the case of a female patient with no cardiovascular risk factor who developed ST-elevation myocardial infraction 30 minutes after ingesting oral sumatriptan for her migraine.

Metrics

Metrics Loading ...

References

Cady RK, Wendt JK, Kirchner JR. The treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-5.

The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-21.

Stricker BH. Coronary vasospasm and sumatriptan. BMJ. 1002;305:118.

Davies MB, Krishnan A. Atrial fibrillation induced by sumatriptan. Cephalalgia. 2005;25:924-5.

O’Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infraction. Neurol. 1995;45:2274-6.

Ottervanger JP, Pealman HJ, Boxma GL. Transmural myocardial infraction with sumatriptan. Lancet. 1993;341:861-2.

Plosay JJ, O’Connell TX. Acute coronary vasospasm resulting from sumatriptan administration in a patient with Raynaud’s disease. Hosp Physician. 2002;38:51-4.

VanDenBrink MA, Reekers M, Bax WA. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98(1):25-30.

Mikhail GW, Airoldi F, Columbo A. Acute myocardial infraction following the use of antimigraine therapy. J Invasive Cardiol. 2004;16(10):602-3.

Inman W, Kubota K. Cardiorespiratory distress after sumatriptan given by ingestion. BMJ. 1992;305(6855):713-4.

Laine K, Raasalkka T. Fatal cardiac arrhythmia after oral sumatriptan. Headache. 1999;39(7):511-2.

Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved in therapeutic implications. Arch Pharmacol. 2007;376(1-2):45-63.

McIntyre PD, Bhargava B, Hogg KJ. The effect of subcutaneous sumatriptan on the systemic, pulmonary and coronary circulation. Circulation. 1993;87:401-5.